Publication:
Drug repositioning screen on a new primary cell line identifies potent therapeutics for glioblastoma

dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAksu, Ali Cenk
dc.contributor.kuauthorBörklü Yücel, Esra
dc.contributor.kuauthorCingöz, Ahmet
dc.contributor.kuauthorÖnder, Tuğba Bağcı
dc.contributor.kuauthorŞeker-Polat, Fidan
dc.contributor.kuauthorŞenbabaoğlu, Filiz
dc.contributor.kuauthorSolaroğlu, İhsan
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:13:10Z
dc.date.issued2020
dc.description.abstractGlioblastoma is a malignant brain cancer with limited treatment options and high mortality rate. While established glioblastoma cell line models provide valuable information, they ultimately lose most primary characteristics of tumors under long-term serum culture conditions. Therefore, established cell lines do not necessarily recapitulate genetic and morphological characteristics of real tumors. In this study, in line with the growing interest in using primary cell line models derived from patient tissue, we generated a primary glioblastoma cell line, KUGBM8 and characterized its genetic alterations, long term growth ability, tumor formation capacity and its response to Temozolomide, the front-line chemotherapy utilized clinically. In addition, we performed a drug repurposing screen on the KUGBM8 cell line to identify FDA-approved agents that can be incorporated into glioblastoma treatment regimen and identified Topotecan as a lead drug among 1,200 drugs. We showed Topotecan can induce cell death in KUGBM8 and other primary cell lines and cooperate with Temozolomide in low dosage combinations. Together, our study provides a new primary cell line model that can be suitable for both in vitro and in vivo studies and suggests that Topotecan can offer promise as a therapeutic approach for glioblastoma.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume14
dc.identifier.doi10.3389/fnins.2020.578316
dc.identifier.eissn1662-453X
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR02643
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85098548475
dc.identifier.urihttps://hdl.handle.net/20.500.14288/1218
dc.identifier.wos603620100001
dc.keywordsGlioblastoma
dc.keywordsPrimary cell line
dc.keywordsDrug repurposing
dc.keywordsTopotecan
dc.keywordsTemozolomide
dc.language.isoeng
dc.publisherFrontiers
dc.relation.grantnoNA
dc.relation.ispartofFrontiers in Neuroscience
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/9290
dc.subjectMedicine
dc.subjectNeurosciences
dc.titleDrug repositioning screen on a new primary cell line identifies potent therapeutics for glioblastoma
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorŞenbabaoğlu, Filiz
local.contributor.kuauthorCingöz, Ahmet
local.contributor.kuauthorŞeker-Polat, Fidan
local.contributor.kuauthorÖnder, Tuğba Bağcı
local.contributor.kuauthorAksu, Ali Cenk
local.contributor.kuauthorBörklü Yücel, Esra
local.contributor.kuauthorSolaroğlu, İhsan
local.publication.orgunit1GRADUATE SCHOOL OF HEALTH SCIENCES
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
local.publication.orgunit2Graduate School of Health Sciences
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery4c75e0a5-ca7f-4443-bd78-1b473d4f6743

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
9290.pdf
Size:
4.18 MB
Format:
Adobe Portable Document Format